AstraZeneca Surpasses Q3 Expectations with Robust Revenue Growth ...Middle East

Devdiscourse - Opinion
AstraZeneca Surpasses Q3 Expectations with Robust Revenue Growth
AstraZeneca has delivered an impressive financial performance in the third quarter of 2024, surpassing market expectations. The pharmaceutical giant reported a core EPS of $2.08, eclipsing the IBES estimate of $2.01, and total revenue of $13,565 million, which exceeded the forecasted $13,046 million.

Read More Details
Finally We wish PressBee provided you with enough information of ( AstraZeneca Surpasses Q3 Expectations with Robust Revenue Growth )

Also on site :



Latest News